Thymosin beta 4 and the eye: the journey from bench to bedside
Sosne G (2018). Expert Opinion on Biological Therapy.
Summary
A first-person account by one of the investigators of how thymosin beta-4 moved from laboratory work into eye clinics, covering its applications in ocular repair and reporting that phase 3 clinical trials of the peptide in dry eye and neurotrophic keratopathy were under way at the time of writing. It is the clearest published statement that the molecule reached late-stage human trials, and it is explicitly a personal narrative rather than a systematic review. As with the cardiac work, the trials concern the full protein rather than the TB-500 fragment.